Tozinameran
Tozinameran is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2. Trials began in April 2020; by November, the vaccine had been tested on more than 40,000 people. Pfizer indicated in November 2020, that 50 million doses could be available globally by the end of 2020, with about 1.3billion doses in 2021.
